<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D1DA0BDF-FF53-4D5B-94F4-7C662BC0A62D"><gtr:id>D1DA0BDF-FF53-4D5B-94F4-7C662BC0A62D</gtr:id><gtr:firstName>Edward Alexander</gtr:firstName><gtr:surname>McKenzie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A04056CD-D71B-4353-AC80-88684D933157"><gtr:id>A04056CD-D71B-4353-AC80-88684D933157</gtr:id><gtr:firstName>Tom</gtr:firstName><gtr:surname>Blanchard</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/986260D7-C7E0-4E29-88EF-0390CF56866D"><gtr:id>986260D7-C7E0-4E29-88EF-0390CF56866D</gtr:id><gtr:firstName>Pamela</gtr:firstName><gtr:surname>Vallely</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_15104"><gtr:id>CEF03BBA-740C-4DFD-906C-E6267DDF4611</gtr:id><gtr:title>Zika: a safe recombinant vaccine with proof of efficacy in rodents</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_15104</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>We will construct a recombinant modified vaccinia Ankara (MVA) Zika virus vaccine in Manchester, and obtain proof of protection in a rodent model of Zika infection under development at Porton Down.
Recombinant modified vaccinia Ankara has been widely used as a human vaccine candidate. MVA has an excellent safety record, does not replicate in mammals, has a desirable cytokine receptor profile, and is particularly immunogenic when employed as a boosting agent(1-3). Such a vaccine would be suitable for large-scale use across whole populations giving simultaneous protection whilst interrupting the transmission of Zika.
Recombinant MVA has already been employed to generate vaccine candidates for related flaviviruses such as Japanese B encephalitis virus (JEV) and dengue(4-6). These employ prM and E sequences, sometimes truncated. We will employ capsid sequences as well, in order to generate more immunogenic virus-like particles. Recombinant vaccines such as these may be difficult to generate because of syncytia formation in which case strategies such as T7 expression system regulated by coinfection will be employed.
Licensed vaccines for the closely related dengue virus and for JEV do exist. In the case of the Sanofi-Pasteur dengue vaccine this is based on recombinant variants of the 17D yellow fever vaccine: there would be concern that an equivalent Zika vaccine might be embryotoxic. The JEV vaccine is an inactivated derivative of JEV: manufacture of such a vaccine would require large scale production of Zika (not possible at present) and always carries the risk of environmental release or failure of inactivation.</gtr:technicalSummary><gtr:fund><gtr:end>2017-10-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-03-31</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>55200</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation to Advanced Medicine Conference at The Royal College of Physicians of London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A218C4EE-6720-49ED-AF50-773A63EDAE30</gtr:id><gtr:impact>Presentation on &amp;quot;what's new in vaccines&amp;quot; at the RCP in London on 14/2/16 which included a description of the prospects for a Zika vaccine</gtr:impact><gtr:outcomeId>58b2ee200d7c19.73641349</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.rcplondon.ac.uk/events/advanced-medicine-1</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Manchester Medical Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6D15E496-0DB7-4E71-89EC-AE9CD6711AFF</gtr:id><gtr:impact>Invited presentation on 8/2/16 to Medicine and Pathology Sections of Manchester Medical Society on Zika. Discussed epidemiology, pathology, clinical syndromes and prospects for a vaccine against Zika.</gtr:impact><gtr:outcomeId>58b2eb4a961748.35716703</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.mms.org.uk/</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Arbovirus update at Liverpool Medical Institution</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6F1B0BE8-344C-4DF6-98B8-60ADFA9509D5</gtr:id><gtr:impact>I chaired the Infectious Diseases Mersey Teach-In at the Liverpool Medical Institution on 7th February 2017. This was attended by 121 individuals, mostly medical doctors, undergraduate and postgraduate students, and yielded the highest recorded attendance for such an event. As part of the teach-in I gave a presentation on arboviruses, including the latest information on the Zika pandemic and a brief overview of our vaccine research. The feedback was all very good to excellent.</gtr:impact><gtr:outcomeId>58b1cd2c02e1d6.46597912</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.rcplondon.ac.uk/events/teach-infectious-diseases-mersey-region-0</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_15104</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes><gtr:rcukProgramme><gtr:id>C11BDEA9-7D9D-4728-B6A9-31032921B328</gtr:id><gtr:text>Newton</gtr:text></gtr:rcukProgramme></gtr:rcukProgrammes></gtr:project></gtr:projectComposition></gtr:projectOverview>